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Abstract 52 
Dipeptidyl peptidase IV (DPP-IV) inhibitors are promising new therapies for type 2 53 
diabetes. Therefore, the aim of this study was to identify DPP-IV inhibitory peptides 54 
present in a water soluble extract of Spanish dry-cured ham. Such extract was 55 
fractionated by size-exclusion chromatography and the in vitro DPP-IV inhibitory 56 
activity was determined in each collected fraction. Several peptides present in the active 57 
fractions were synthesised and assayed for DPP-IV inhibition. Peptides KA and 58 
AAATP showed the strongest DPP-IV inhibitory activity, with IC50 values of 6.27 mM 59 
and 6.47 mM, respectively. Dipeptides AA, GP, PL, and carnosine, as well as peptides 60 
AAAAG, ALGGA, and LVSGM also demonstrated to be DPP-IV inhibitors, although 61 
at a lower degree. These findings suggest the potential of Spanish dry-cured ham as a 62 
natural precursor of DPP-IV inhibitory peptides. These biopeptides could also be used 63 
as ingredients for functional foods or pharmaceutical products against type 2 diabetes.   64 
 65 
 66 
 67 
 68 
 69 
 70 
Keywords: Dry-cured ham, bioactive peptides, dipeptidyl peptidase IV inhibitor, type 2 71 
diabetes. 72 
73 
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1. Introduction 74 
Dipeptidyl peptidase IV (DPP-IV) is a serine protease expressed in both membrane and 75 
soluble forms in a diversity of cell types. This enzyme cleaves preferentially X-proline 76 
or X-alanine dipeptides from N-terminus of multiple substrates, including incretin 77 
hormones named glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic 78 
peptide (GIP) (Cunningham & O’Connor, 1997; Thoma, Löffler, Stihle, Huber, Ruf & 79 
Henning, 2003). GLP-1 and GIP are gut-derived peptides secreted in response to 80 
nutrient ingestion that potentiate glucose-stimulated insulin release by the pancreas, 81 
suppress glucagon secretion and improve plasma glucose concentrations. Nevertheless, 82 
incretin hormones are quickly degraded by the ubiquitous DPP-IV (Mudaliar & Henry, 83 
2012).  84 
Recent advances in the understanding of incretins have led to the development of two 85 
main classes of GLP-1-mediated therapies against type 2 diabetes: GLP-1 receptor 86 
agonists resistant to degradation by DPP-IV, and DPP-IV inhibitors that reduce the 87 
degradation of GLP-1. The choice of the therapy to be used depends on the speciﬁc 88 
needs of the diabetic patient (Fineman, Cirincione, Maggs & Diamant, 2012). GLP-1 89 
agonists are intravenously administered and offer higher target selectivity but they 90 
present undesirable side effects. Alternatively, DPP-IV inhibitors are orally 91 
administered and cause only transient and minimal side effects. Several synthetic DPP-92 
IV inhibitors have emerged in recent years as potent antidiabetic drugs, for example 93 
vildagliptin, sitagliptin, saxagliptin, and linagliptin (Pratley & Gilbert, 2008; Fineman et 94 
al., 2012). 95 
DPP-IV inhibitors extend the half-life of the endogenous GLP-1 and GIP and 96 
consequently their plasma concentrations increase. Then, these incretin hormones 97 
enhance glucose-dependent insulin secretion, reduce glucagon production and hepatic 98 
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glucose production, and other glycaemic effects. Notably GLP-1 is more effective than 99 
GIP in stimulating insulin release at an equivalent level of glycaemia. Furthermore, 100 
GLP-IV and GIP are also involved in extra-glycaemic effects such as improve β-cell 101 
function, and cardiovascular and central nervous system effects (Mudaliar & Henry, 102 
2012; Duez, Cariou & Staels, 2012). 103 
There are some reports describing bioactive peptides with DPP-IV inhibitory activity, 104 
and a recent in silico approach can be used to identify potential dietary proteins as 105 
precursors of DPP-IV inhibitors (Lacroix & Li-Chan, 2012). Some of these inhibitory 106 
peptides were found in salmon, bovine meat, chicken egg, milk, wheat, rice bran, and 107 
others (Lacroix & Li-Chan, 2012; Li-Chan, Hunag, Jao, Ho & Hsu, 2012; Hatanaka et 108 
al., 2012). Most of the inhibitory peptides contain proline and/or hydrophobic amino 109 
acids within their sequence, and the third N-terminal residue of the peptide plays an 110 
important role in determining the inhibitory activity of a peptide (Hatanaka et al., 2012). 111 
Thus, the DPP-IV inhibitory activity of such peptides is determined by their 112 
composition and sequence of amino acids but not by their length (Huang, Jao, Ho & 113 
Hsu, 2012). 114 
Spanish dry-cured ham has been studied as a natural source of bioactive peptides with 115 
antihypertensive and antioxidant activity (Escudero, Mora, Fraser, Aristoy, Arihara & 116 
Toldrá, 2013a; Escudero, Mora, Fraser, Aristoy & Toldrá, 2013b), but according to our 117 
knowledge, to date there are no studies about DPP-IV inhibitory peptides present in dry-118 
cured ham. The purpose of the present study was to verify the existence of peptides, 119 
present in water soluble fractions of dry-cured ham, with inhibitory activity against 120 
DPP-IV.  121 
 122 
2. Materials and methods 123 
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2.1 Reagents 124 
Dipeptidyl peptidase IV (from porcine kidney), Diprotin A (Ile-Pro-Ile), Gly-Pro-7-125 
amido-4-methylcoumarin hydrobromide (Gly-Pro-AMC), DL-Dithiothreitol (DTT), 126 
trifluoroacetic acid (TFA) and the synthetic peptides Ala-Ala (AA), Lys-Ala (KA), Gly-127 
Pro (GP), Pro-Leu (PL), L-carnosine, L-anserine nitrate salt, and L-glutathione reduced 128 
(GSH) were purchased from Sigma-Aldrich, Co. (St. Louis, Mo., USA). 129 
Ethylenediaminetetraacetic Acid Disodium salt 2-hydrate (EDTA) was from Panreac 130 
Química, S.L.U. (Barcelona, Spain) and Acetonitrile HPLC grade was from Sharlab, 131 
S.L. (Barcelona, Spain). All other chemicals and reagents used were of analytical grade. 132 
2.2 Spanish dry-cured ham preparation 133 
Three Spanish dry-cured hams were produced using raw hams from 6 months old pig 134 
(Landrace x Large White). Hams were bled and prepared according to traditional 135 
procedures consisting of the pre-salting stage using a mixture of salt, nitrate and nitrite, 136 
the salting state where hams were covered with solid salt, piled up and placed in a cold 137 
room (2-4 ºC and 90-95% relative humidity for 12 days), post-salting where hams were 138 
kept at 4-5 ºC, 75-85% relative humidity for 60 days, and finally, the ripening-drying 139 
period at 14-20 ºC and relative humidity down to 70%. The total length of the curing 140 
process was 10 months. 141 
2.3 Extraction and deproteinisation 142 
Fifty grams of Biceps femoris muscle from the processed Spanish dry-cured hams were 143 
minced and homogenised with 200 mL of 0.01 N HCl for 8 minutes in a stomacher 144 
(IUL Instrument, Barcelona, Spain). The homogenate was centrifuged (12000 g for 20 145 
min at 4 ºC), filtered through glass wool and then the supernatant was deproteinised by 146 
adding 3 volumes of ethanol and maintaining the sample at 4 ºC for 20 hours. Next, the 147 
sample was centrifuged again (12000 g for 10 min at 4 ºC) and the supernatant was 148 
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 6 
dried in a rotatory evaporator and then lyophilised for further ultrafiltration, as 149 
described in 2.4. The same procedure was followed for the size-exclusion 150 
chromatography as described in 2.5. In this case, the extract was dissolved in 25 mL of 151 
0.01 N HCl, filtered through a 0.45 µm nylon membrane filter (Millipore, Bedford, 152 
MA) and stored at -20 ºC until use. 153 
2.4 Ultrafiltration 154 
An aliquot of the deproteinised extract was fractionated by ultrafiltration using a 155 
Microcon microconcentrator model 3 (Amicon, Inc., MA, USA) and a Microsep™ UF 156 
Spin Filter 1K (Pall Corporation, MI, USA) with membranes having molecular mass 157 
cut-offs of 3 kDa and 1kDa, respectively. The collected fractions contained peptides 158 
between 3-1 kDa and lower than 1kDa, which were assayed for DPP-IV inhibition. 159 
2.5 Size-exclusion chromatography 160 
A 5 mL aliquot of the deproteinised extract was subjected to size-exclusion 161 
chromatography to fractionate the peptides according to their molecular mass. A 162 
Sephadex G25 column (2.5 x 72 cm, Amersham Biosciencies, Uppsala, Sweden) was 163 
employed, previously equilibrated with 0.01 N HCl filtered through a 0.45 µm nylon 164 
membrane filter (Millipore) and degassed.  The separation was performed at 4 ºC and at 165 
a flow rate of 15 mL/h of 0.01 N HCl as eluent. 5 mL fractions were collected using an 166 
automatic fraction collector and further monitored by ultraviolet (UV) absorption at 214 167 
nm (Ultrospec 3000 UV/Visible spectrophotometer, Pharmacia Biotech, Cambridge, 168 
England). The first 105 mL were discarded and the remaining fractions were collected 169 
and grouped as follows: fractions corresponding to elution volumes from 110 mL to 185 170 
mL (named sample 1), from 190 mL to 310 mL (sample 2), from 315 mL to 420 mL 171 
(sample 3), from 425 mL to 475 mL (sample 4) and fractions eluting from 480 mL to 172 
625 mL (sample 5). Each fraction was lyophilised and then was redissolved in 2 mL of 173 
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 7 
50mM Tris-HCl buffer (pH 8.0). For the DPP IV inhibitory assay, each sample was 174 
tested at various concentrations. 175 
2.6 Determination of DPP-IV inhibitory activity 176 
The DPP-IV inhibition assay was carried out using 96-well microplates by measuring 177 
fluorescence due to the release of 7-amido-4-methylcoumarin (AMC) by the action of 178 
DPP IV from the internally quenched fluorescent substrate Gly-Pro-7-amido-4-179 
methylcoumarin hydrobromide (Gly-Pro-AMC). Test samples (50 µL each sample and 180 
dilutions) were added 50 µL of DPP-IV (diluted with 50 mM Tris-HCl buffer pH 8.0 to 181 
4.55 mU/mL). The reaction was initiated by the addition of 200 µL of 0.25 mM reaction 182 
buffer (containing 50 mM Tris-HCl buffer pH 8.0, 5 mM DTT, 1 mM EDTA and 20 183 
mM Gly-Pro-AMC). The mixture was then incubated for 20 min at 37ºC. The 184 
generation of fluorescence was measuring using excitation and emission wavelengths of 185 
355 nm and 460 nm, respectively (Fluoroskan Ascent microplate fluorometer, Thermo 186 
Scientific, MA, USA).  DPP-IV inhibition is expressed as percentage and the IC50 value 187 
was defined as the concentration of sample or peptide required to inhibit 50% of DPP-188 
IV activity. Diprotin A (Ile-Pro-Ile) was used as a reference inhibitor. 189 
2.7 Selection of DPP-IV inhibitory peptides and peptide synthesis 190 
The selection of peptides with potential DPP-IV inhibitory activity among the large 191 
number of them identified in the Spanish dry-cured ham (Sentandreu, Stoeva, Aristoy, 192 
Laib, Voelter & Toldrá, 2003; Sentandreu & Toldrá, 2007; Escudero et al., 2013a) was 193 
done according to the characteristics defined for DPP-IV inhibitory peptides, which 194 
generally are characterized by a hydrophobic nature and in particular by the presence of 195 
a proline or an alanine in position 2 of the N-terminus (Pieter, 2006). Thus, dipeptides 196 
with theoretical DPP-IV inhibitory activity AA, KA, GP, and PL were assayed as well 197 
as the natural meat peptides carnosine, anserine, and glutathione reduced.  198 
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 8 
Other 7 peptides like AAATP, ASGPINFT, DVITGA, SAGPN, AAAAG, ALGGA, and 199 
LVSGM previously identified in dry-cured ham (Escudero et al., 2013a; Escudero et al., 200 
2013b) were also selected for testing DPP-IV inhibitory activity because of their 201 
hydrophobic character in N-terminal residues. These peptides were synthesised by the 202 
solid phase procedure using the Fmoc protected amino acid synthesis method in a Focus 203 
XC (AAPPTec
®
 Louisville, KY, USA). The synthesised peptides were purified by 204 
HPLC (Agilent 1100 HPLC system, Agilent Tech., Palo Alto, CA, USA) and the 205 
column used was a Symmetry C18 (4.6 mm x 250 mm, 5µm) from Waters (Milford, 206 
MA, USA). Mobile phases consisted of solvent A containing 0.1% TFA in water and 207 
solvent B containing 0.085% TFA in acetonitrile:water (60:40, v/v). Both mobile phases 208 
were filtered through a 0.45 µm nylon membrane filter and degassed prior to analytical 209 
run. We used an isocratic gradient of 99% solvent A for 5 min, followed by a linear 210 
gradient from 1% to 100% of solvent B in 80 min at a flow rate of 0.8 mL/min. The 211 
separation was monitored using a diode array detector at a wavelength of 214 nm. The 212 
purity and the molecular mass of the purified peptides were determined in an Ultimate 213 
3000 RSLC nano system from Dionex (Thermo Fisher Scientific Ltd., Leicestershire, 214 
UK) coupled to an AmaZon ETD ion-trap mass spectrometer equipped with an 215 
nanoelectrospray ionisation source (Bruker Daltonik GmbH, Bremen, Germany). 216 
 217 
3. Results and discussion 218 
3.1 DPP-IV inhibitory activity of ultrafiltered fractions 219 
Fractions separated by ultrafiltration were assayed for DPP-IV inhibitory activities 220 
(Figure 1). The results showed that peptides between 3-1 kDa had the highest DPP-IV 221 
inhibition rate of 92.5 %, while peptides < 1 kDa displayed an inhibition rate of 75.2%. 222 
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 9 
Because both groups of ultrafiltered fractions were strong inhibitors, fractions obtained 223 
from gel filtration were also assayed for DPP-IV inhibitory activity. 224 
3.2 DPP-IV inhibitory activity of fractions from gel filtration chromatography 225 
Fractions separated using the Sephadex G-25 gel filtration column (Figure 2) were 226 
assayed for in vitro DPP-IV inhibitory activity at various concentrations: samples 227 
solutions (lyophilized fractions dissolved in 2 mL of 50mM Tris-HCl buffer, pH 8) and 228 
then serially diluted 1/10, 1/100, and 1/1000. 229 
The assays showed that sample 1 (corresponding to an elution volume from 110 to 185 230 
mL) and samples 3, 4 and 5 (corresponding to elution volumes in the ranges 315 to 625 231 
mL) did not exert a remarkable inhibitory effect on DPP-IV activity. Moreover, their 232 
concentrations were 0.19 mg/mL for sample 1, 13.54 mg/mL for sample 3, 1.59 mg/mL 233 
for sample 4 and 7.04 mg/mL for sample 5, each concentration expressed as tyrosine 234 
equivalents measured at 280 nm. 235 
Sample 2 corresponding to an elution volume from 190 mL to 310 mL was the only 236 
sample that showed DPP-IV inhibitory activity, thus it was diluted 1/2, 1/4, 1/10, 1/12.5, 237 
1/20, and 1/100 to determine its IC50 value. This sample corresponded to molecular 238 
mass lower than 1700 Da (Aristoy & Toldrá, 1995) and its concentration was 5.67 239 
mg/mL expressed as tyrosine equivalents. The IC50 value was determined and found to 240 
be 0.69 mg/mL (Figure 3). In addition, we tested the effect of two minerals, sodium and 241 
calcium, on DPP-IV enzyme activity. In dry-cured ham, current levels of salt added in 242 
the curing process result in sodium concentrations within the range 1100-1800 mg/100g, 243 
while calcium is usually between 12 and 35 mg/100g of ham (Jiménez-Colmenero, 244 
Ventanas & Toldrá, 2010). Moreover, former studies showed that the elution of NaCl 245 
from the gel filtration column appeared in fraction corresponding to sample 2 246 
(Sentandreu et al., 2003). Then, CaCl2 and NaCl were tested if affected the inhibition 247 
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 10 
results obtained for sample 2, but the results indicated that both salts were not DPP-IV 248 
inhibitors. 249 
 250 
3.3 DPP-IV inhibitory activity of selected peptides 251 
Four dipeptides identified in dry-cured ham (AA, KA, GP, and PL), three natural meat 252 
peptides (carnosine, anserine and GSH) and other seven dry-cured ham peptides of 253 
greater length (AAATP, ASGPINFT, DVITGA, SAGPN, AAAAG, ALGGA, and 254 
LVSGM) were selected and evaluated for their in vitro activity on DPP-IV. Diprotin A 255 
(Ile-Pro-Ile), which is a well-known peptide with the greatest DPP-IV inhibitory activity, 256 
was used as a control and showed an IC50 value of 11.08 µM as measured under the 257 
present study conditions (Figure 4).  258 
The first four dipeptides were mainly generated by the action of porcine muscle 259 
dipeptidyl peptidases (Sentandreu & Toldrá, 2007) and were selected because they 260 
contain a proline or alanine in the first or second N-terminal residue. The experimental 261 
results indicated that AA and KA were DPP-IV inhibitors with IC50 of 9.40 ± 0.10 mM 262 
and 6.27 ±0.59 mM, respectively. In relation to GP, contradictory results are reported in 263 
the literature with some studies indicating DPP-IV inhibitory activity (Lacroix & Li-264 
Chan, 2012) and other study indicating the opposite (Hatanaka et al., 2012). In our 265 
assay, GP presented inhibitory activity and its IC50 value was 9.69 ± 0.49 mM. PL 266 
peptide showed the lowest inhibitory activity and its IC50 value was found to be greater 267 
than 10 mM (Table 1). 268 
Marušić, Aristoy & Toldrá, 2013, studied and determined the concentrations of natural 269 
meat peptides carnosine, anserine and GSH in Biceps femoris muscle during the 270 
processing of dry-cured ham. At 10 months of ham curing process, concentrations of 271 
carnosine and anserine were 1269.6 mg/100g of ham dry matter (equivalent to 56 mM) 272 
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and 70.9 mg/100g of ham dry matter (equivalent to 2.95 mM), respectively. GSH was 273 
present until 6.5 months of processing but it disappeared at the end of the process (9 and 274 
10 months). This tripeptide was not present in our samples but some commercial hams 275 
with 5-7 months of curing process still contain GSH (approximately 5-10 µM). So, 276 
these natural meat peptides were tested as inhibitors and results indicated that anserine 277 
and GSH did not inhibit the activity of DPP-IV at 10 mM or lower concentrations. 278 
However, carnosine exerted inhibitory activity and its IC50 was 493 ± 4.74 mM (Table 279 
2). Considering the high concentration of carnosine (56 mM) present in ham after 10 280 
months of processing, this value would represent an inhibition rate of 13%.  281 
Regarding to the seven synthesised peptides, all of them were identified previously in 282 
dry-cured ham. AAATP, ASGPINFT, and DVITGA were described as antihypertensive 283 
peptides, whereas SAGPN did not show ACE inhibitory activity (Escudero et al., 284 
2013a), and AAAAG, ALGGA, and LVSGM were described as antioxidant peptides 285 
(Escudero et al., 2013b). More peptides were also identified but only those having a 286 
length between 2 to 8 amino acids and a hydrophobic nature within the peptide 287 
sequence, particularly a proline or an alanine in the first or second N-terminal residue, 288 
were selected. As can be seen in Table 1, AAATP was the strongest DPP-IV inhibitor 289 
with an IC50 value of 6.47 ± 0.20 mM, while AAAAG showed an IC50 value of 8.13 ± 290 
0.48 mM. Peptides ALGGA and LVSGM were also DPP-IV inhibitors but their IC50 291 
were greater than 10 mM, and ASGPINFT, DVITGA, and SAGPN did not exert 292 
inhibitory activity up to 20 mM. 293 
DPP-IV inhibitory peptides AAAAG, ALGGA, and LVSGM were identified in 294 
fractions, from size-exclusion chromatography, corresponding to our sample 2 295 
(Escudero et al., 2013b), which is in agreement with the high DPP-IV inhibitory activity 296 
showed previously in this sample. However, AAATP was identified in fraction 297 
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corresponding to our sample 3 and it was originated from Sus scrofa allantoicase protein 298 
(Escudero et al., 2013a). No inhibitory activity was detected in sample 3, probably due 299 
to the low amount of AAATP originated from a minor protein (allantoicase) in ham. 300 
These findings are of interest because peptides generated in dry-cured ham may act as a 301 
natural therapeutic approach for the management of type 2 diabetes, although these are 302 
not as potent as the synthetic drugs. In addition, these biopeptides could be isolated 303 
from dry-cured ham and then be added as ingredients in products marketed as 304 
‘Functional Foods’ or ‘Natraceuticals’, or they could be used as ingredients of 305 
pharmaceutical products against type 2 diabetes (Pihlanto & Korhonen, 2003; Hartmann 306 
& Meisel, 2007; Ryan, Ross, Bolton, Fitzgerald & Stanton, 2011). 307 
 308 
4. Conclusions 309 
This study reports, for the first time in Spanish dry-cured ham, the synthesis and assay 310 
for DPP-IV inhibitory activity of previously reported peptides that have been either 311 
identified in dry-cured ham or known to be products of DPP IV action. Nine peptides 312 
were shown to inhibit DPP-IV enzyme of which KA and AAATP were the most potent 313 
inhibitors, with IC50 values of 6.27 mM and 6.47 mM, respectively. Therefore, dry-314 
cured ham could serve as natural precursor of peptides with inhibitory effect on DPP-IV, 315 
and these biopeptides could be used as a natural complementary treatment in the 316 
prevention and management of type 2 diabetes. However, further research is needed to 317 
identify novel peptides responsible for DPP-IV inhibition in dry-cured ham or test a 318 
possible synergistic effect among various inhibitory peptides identified. Moreover, 319 
future in vivo studies will need to be performed to validate the in vitro DPP-IV 320 
inhibitory activity and confirm the bioavailability and efficacy of these bioactive 321 
peptides.  322 
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FIGURES CAPTIONS 413 
Figure 1. DPP-IV inhibitory activity of dry-cured ham extract fractionated by 414 
ultrafiltration. 415 
 416 
Figure 2. Fractionation of dry-cured ham extract in a Sephadex G-25 gel filtration 417 
column. Fractions were collected and tested for DPP-IV inhibitory activity. Fractions 418 
corresponding to elution volumes from 110 to 185 mL were pooled and named sample 1 419 
(S1). The same procedure was followed for fractions corresponding to elution volumes 420 
from 190 to 310 mL (S2), fractions from 315 to 420 mL (S3), fractions from 425 to 475 421 
mL (S4) and fractions from 480 to 625 mL (S5). 422 
 423 
Figure 3. DPP-IV inhibition rate and IC50 value of sample 2 at various concentrations. 424 
Bars represent standard deviations from triplicate determinations. DPP IV inhibition is 425 
regressed on ln (x) of concentration.  426 
 427 
Figure 4. DPP-IV inhibition rate and IC50 value of diprotin A at various concentrations. 428 
Bars represent standard deviations from triplicate determinations. DPP IV inhibition is 429 
regressed on ln (x) of concentration.  430 
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Table 1. IC50 (mM) values of diprotin A (reference inhibitor) and synthetic peptides 
against DPP-IV activity. 
Peptides IC50 (mM) 
Diprotin A 0.011 ± 0.001 
KA 6.27 ± 0.59 
AA 9.40 ± 0.10 
GP 9.69 ± 0.49 
PL > 10 
AAATP 6.47 ± 0.20 
AAAAG 8.13 ± 0.48 
ALGGA > 10 
LVSGM > 10 
ASGPINFT No inhibition * 
DVITGA No inhibition * 
SAGPN No inhibition * 
* Tested up to 20 mM of peptide. 
 
Table 2. IC50 (mM) value of natural meat peptides against DPP-IV activity. 
Natural meat peptides IC50 (mM) 
Carnosine 493 ± 4.74 
#
 
Anserine No inhibition * 
Glutathione reduced No inhibition * 
#
 Carnosine concentration after 10 months of ham curing process is very high (56 mM). 
*
 
Tested up to 10 mM of peptide. 
 
Tables 1 and 2
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
 
 
 
Dipeptidyl peptidase IV inhibitory peptides generated in Spanish Dry-
Cured ham 5 
 
 
 
Marta Gallego, Maria-Concepción Aristoy, and
 
Fidel Toldrá
*
 
 
10 
 
Instituto
 
de Agroquímica y Tecnología de Alimentos (CSIC), Avd. Agustín Escardino 7, 46980, Paterna, 
Valencia, Spain 
 
 15 
 
 
 
 
 20 
 
 
 
 
 25 
 
 
 
 
 30 
 
 
 
 
 35 
 
 
 
 
 40 
 
 
 
 
 45 
 
 
*
 Corresponding author: Tel: +34963900022 ext.2112; fax: +34963636301.  
E-mail address: ftoldra@iata.csic.es 
 50 
 
*Manuscript
Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 2 
Abstract 
Dipeptidyl peptidase IV (DPP-IV) inhibitors are promising new therapies for type 2 
diabetes. Therefore, the aim of this study was to identify DPP-IV inhibitory peptides 
present in a water soluble extract of Spanish dry-cured ham. Such extract was 55 
fractionated by size-exclusion chromatography and the in vitro DPP-IV inhibitory 
activity was determined in each collected fraction. Several peptides present in the active 
fractions were identified, synthetised and assayed for DPP-IV inhibition. Peptides KA 
and AAATP showed the strongest DPP-IV inhibitory activity, with IC50 values of 6.27 
mM and 6.47 mM, respectively. Dipeptides AA, GP, PL, and carnosine, as well as 60 
peptides AAAAG, ALGGA, and LVSGM also demonstrated to be DPP-IV inhibitors, 
although at a lower degree. These findings suggest the potential of Spanish dry-cured 
ham as a natural precursor of DPP-IV inhibitory peptides. These biopeptides could also 
be used as ingredients for functional foods or pharmaceutical products against type 2 
diabetes.   65 
 
 
 
 
 70 
 
Keywords: Dry-cured ham, bioactive peptides, dipeptidyl peptidase IV inhibitor, type 2 
diabetes. 
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1. Introduction 75 
Dipeptidyl peptidase IV (DPP-IV) is a serine protease expressed in both membrane and 
soluble forms in a diversity of cell types. This enzyme cleaves preferentially X-proline 
or X-alanine dipeptides from N-terminus of multiple substrates, including incretin 
hormones named glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic 
peptide (GIP) (Cunningham & O’Connor, 1997; Thoma, Löffler, Stihle, Huber, Ruf & 80 
Henning, 2003). GLP-1 and GIP are gut-derived peptides secreted in response to 
nutrient ingestion that potentiate glucose-stimulated insulin release by the pancreas, 
suppress glucagon secretion and improve plasma glucose concentrations. Nevertheless, 
incretin hormones are quickly degraded by the ubiquitous DPP-IV (Mudaliar & Henry, 
2012).  85 
Recent advances in the understanding of incretins have led to the development of two 
main classes of GLP-1-mediated therapies against type 2 diabetes: GLP-1 receptor 
agonists resistant to degradation by DPP-IV, and DPP-IV inhibitors that reduce the 
degradation of GLP-1. The choice of the therapy to be used depends on the speciﬁc 
needs of the diabetic patient (Fineman, Cirincione, Maggs & Diamant, 2012). GLP-1 90 
agonists are intravenously administered and offer higher target selectivity but they 
present undesirable side effects. Alternatively, DPP-IV inhibitors are orally 
administered and cause only transient and minimal side effects. Several synthetic DPP-
IV inhibitors have emerged in recent years as potent antidiabetic drugs, for example 
vildagliptin, sitagliptin, saxagliptin, and linagliptin (Pratley & Gilbert, 2008; Fineman et 95 
al., 2012). 
DPP-IV inhibitors extend the half-life of the endogenous GLP-1 and GIP and 
consequently their plasma concentrations increase. Then, these incretin hormones 
enhance glucose-dependent insulin secretion, reduce glucagon production and hepatic 
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 4 
glucose production, and other glycaemic effects. Notably GLP-1 is more effective than 100 
GIP in stimulating insulin release at an equivalent level of glycaemia. Furthermore, 
GLP-IV and GIP are also involved in extra-glycaemic effects such as improve β-cell 
function, and cardiovascular and central nervous system effects (Mudaliar et al., 2012; 
Duez, Cariou & Staels, 2012). 
There are some reports describing bioactive peptides with DPP-IV inhibitory activity, 105 
and a recent in silico approach can be used to identify potential dietary proteins as 
precursors of DPP-IV inhibitors (Lacroix et al., 2012). Some of these inhibitory 
peptides were found in salmon, bovine meat, chicken egg, milk, wheat, rice bran, and 
others (Lacroix et al., 2012; Li-Chan, Hunag, Jao, Ho & Hsu, 2012; Hatanaka et al., 
2012). Most of the inhibitory peptides contain proline and/or hydrophobic amino acids 110 
within their sequence, and the third N-terminal residue of the peptide plays an important 
role in determining the inhibitory activity of a peptide (Hatanaka et al., 2012). Thus, the 
DPP-IV inhibitory activity of such peptides is determined by their composition and 
sequence of amino acids but not by their length (Huang, Jao, Ho & Hsu, 2012). 
Spanish dry-cured ham has been studied as a natural source of bioactive peptides with 115 
antihypertensive and antioxidant activity (Escudero, Mora, Fraser, Aristoy, Arihara & 
Toldrá, 2013a; Escudero, Mora, Fraser, Aristoy & Toldrá, 2013b), but according to our 
knowledge, to date there are no studies about DPP-IV inhibitory peptides present in dry-
cured ham. The purpose of the present study was to verify the existence of peptides, 
present in water soluble fractions of dry-cured ham, with inhibitory activity against 120 
DPP-IV.  
 
2. Materials and methods 
2.1 Reagents 
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 5 
Dipeptidyl peptidase IV (from porcine kidney), Diprotin A (Ile-Pro-Ile), Gly-Pro-7-125 
amido-4-methylcoumarin hydrobromide (Gly-Pro-AMC), DL-Dithiothreitol (DTT), 
trifluoroacetic acid (TFA) and the synthetic peptides Ala-Ala (AA), Lys-Ala (KA), Gly-
Pro (GP), Pro-Leu (PL), L-carnosine, L-anserine nitrate salt, and L-glutathione reduced 
(GSH) were purchased from Sigma-Aldrich, Co. (St. Louis, Mo., USA). 
Ethylenediaminetetraacetic Acid Disodium salt 2-hydrate (EDTA) was from Panreac 130 
Química, S.L.U. (Barcelona, Spain) and Acetonitrile HPLC grade was from Sharlab, 
S.L. (Barcelona, Spain). All other chemicals and reagents used were of analytical grade. 
2.2 Spanish dry-cured ham preparation 
Three Spanish dry-cured hams were produced using raw hams from 6 months old pig 
(Landrace x Large White). Hams were bled and prepared according to traditional 135 
procedures consisting of the pre-salting stage using a mixture of salt, nitrate and nitrite, 
the salting state where hams were covered with solid salt, piled up and placed in a cold 
room (2-4 ºC and 90-95% relative humidity for 12 days), post-salting where hams were 
kept at 4-5 ºC, 75-85% relative humidity for 60 days, and finally, the ripening-drying 
period at 14-20 ºC and relative humidity down to 70%. The total length of the curing 140 
process was 10 months. 
2.3 Extraction and deproteinisation 
Fifty grams of Biceps femoris muscle from the processed Spanish dry-cured hams were 
minced and homogenised with 200 mL of 0.01 N HCl for 8 minutes in a stomacher 
(IUL Instrument, Barcelona, Spain). The homogenate was centrifuged (12000 g for 20 145 
min at 4 ºC), filtered through glass wool and then the supernatant was deproteinised by 
adding 3 volumes of ethanol and maintaining the sample at 4 ºC for 20 hours. Next, the 
sample was centrifuged again (12000 g for 10 min at 4 ºC) and the supernatant was 
dried in a rotatory evaporator and then lyophilised for further ultrafiltration, as 
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 6 
described in 2.4. The same procedure was followed for the size-exclusion 150 
chromatography as described in 2.5. In this case, the extract was dissolved in 25 mL of 
0.01 N HCl, filtered through a 0.45 µm nylon membrane filter (Millipore, Bedford, 
MA) and stored at -20 ºC until use. 
2.4 Ultrafiltration 
An aliquot of the deproteinised extract was fractionated by ultrafiltration using a 155 
Microcon microconcentrator model 3 (Amicon, Inc., MA, USA) and a Microsep™ UF 
Spin Filter 1K (Pall Corporation, MI, USA) with membranes having molecular mass 
cut-offs of 3 kDa and 1kDa, respectively. The collected fractions contained peptides 
between 3-1 kDa and lower than 1kDa, which were assayed for DPP-IV inhibition. 
2.5 Size-exclusion chromatography 160 
A 5 mL aliquot of the deproteinised extract was subjected to size-exclusion 
chromatography to fractionate the peptides according to their molecular mass. A 
Sephadex G25 column (2.5 x 72 cm, Amersham Biosciencies, Uppsala, Sweden) was 
employed, previously equilibrated with 0.01 N HCl filtered through a 0.45 µm nylon 
membrane filter (Millipore) and degassed.  The separation was performed at 4 ºC and at 165 
a flow rate of 15 mL/h of 0.01 N HCl as eluent. 5 mL fractions were collected using an 
automatic fraction collector and further monitored by ultraviolet (UV) absorption at 214 
nm (Ultrospec 3000 UV/Visible spectrophotometer, Pharmacia Biotech, Cambridge, 
England). The first 105 mL were discarded and the remaining fractions were collected 
and grouped as follows: fractions corresponding to elution volumes from 110 mL to 185 170 
mL (named sample 1), from 190 mL to 310 mL (sample 2), from 315 mL to 420 mL 
(sample 3), from 425 mL to 475 mL (sample 4) and fractions eluting from 480 mL to 
625 mL (sample 5). Each fraction was lyophilised and then was redissolved in 2 mL of 
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 7 
50mM Tris-HCl buffer (pH 8.0). For the DPP IV inhibitory assay, each sample was 
tested at various concentrations. 175 
2.6 Determination of DPP-IV inhibitory activity 
The DPP-IV inhibition assay was carried out using 96-well microplates by measuring 
fluorescence due to the release of 7-amido-4-methylcoumarin (AMC) by the action of 
DPP IV from the internally quenched fluorescent substrate Gly-Pro-7-amido-4-
methylcoumarin hydrobromide (Gly-Pro-AMC). Test samples (50 µL each sample and 180 
dilutions) were added 50 µL of DPP-IV (diluted with 50 mM Tris-HCl buffer pH 8.0 to 
4.55 mU/mL). The reaction was initiated by the addition of 200 µL of 0.25 mM reaction 
buffer (containing 50 mM Tris-HCl buffer pH 8.0, 5 mM DTT, 1 mM EDTA and 20 
mM Gly-Pro-AMC). The mixture was then incubated for 20 min at 37ºC. The 
generation of fluorescence was measuring using excitation and emission wavelengths of 185 
355 nm and 460 nm, respectively (Fluoroskan Ascent microplate fluorometer, Thermo 
Scientific, MA, USA).  DPP-IV inhibition is expressed as percentage and the IC50 value 
was defined as the concentration of sample or peptide required to inhibit 50% of DPP-
IV activity. Diprotin A (Ile-Pro-Ile) was used as a reference inhibitor. 
2.7 Selection of DPP-IV inhibitory peptides and peptide synthesis 190 
The selection of peptides with potential DPP-IV inhibitory activity among the large 
number of them identified in the Spanish dry-cured ham (Sentandreu, Stoeva, Aristoy, 
Laib, Voelter & Toldrá, 2003; Sentandreu & Toldrá, 2007; Escudero et al., 2013a) was 
done according to the characteristics defined for DPP-IV inhibitory peptides, which 
generally are characterized by a hydrophobic nature and in particular by the presence of 195 
a proline or an alanine in position 2 of the N-terminus (Pieter, 2006). Thus, dipeptides 
with theoretical DPP-IV inhibitory activity AA, KA, GP, and PL were assayed as well 
as the natural meat peptides carnosine, anserine, and glutathione reduced.  
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Other 7 peptides like AAATP, ASGPINFT, DVITGA, SAGPN, AAAAG, ALGGA, and 
LVSGM previously identified in dry-cured ham (Escudero et al., 2013a; Escudero et al., 200 
2013b) were also selected for testing DPP-IV inhibitory activity because of their 
hydrophobic character in N-terminal residues. These peptides were synthetised by the 
solid phase procedure using the Fmoc protected amino acid synthesis method in a Focus 
XC (AAPPTec
®
 Louisville, KY, USA). The synthesised peptides were purified by 
HPLC (Agilent 1100 HPLC system, Agilent Tech., Palo Alto, CA, USA) and the 205 
column used was a Symmetry C18 (4.6 mm x 250 mm, 5µm) from Waters (Milford, 
MA, USA). Mobile phases consisted of solvent A containing 0.1% TFA in water and 
solvent B containing 0.085% TFA in acetonitrile:water (60:40, v/v). Both mobile phases 
were filtered through a 0.45 µm nylon membrane filter and degassed prior to analytical 
run. We used an isocratic gradient of 99% solvent A for 5 min, followed by a linear 210 
gradient from 1% to 100% of solvent B in 80 min at a flow rate of 0.8 mL/min. The 
separation was monitored using a diode array detector at a wavelength of 214 nm. The 
purity and the molecular mass of the purified peptides were determined in an Ultimate 
3000 RSLC nano system from Dionex (Thermo Fisher Scientific Ltd., Leicestershire, 
UK) coupled to an AmaZon ETD ion-trap mass spectrometer equipped with an 215 
nanoelectrospray ionisation source (Bruker Daltonik GmbH, Bremen, Germany). 
 
3. Results and discussion 
3.1 DPP-IV inhibitory activity of ultrafiltered fractions 
Fractions separated by ultrafiltration were assayed for DPP-IV inhibitory activities 220 
(Figure 1). The results showed that peptides between 3-1 kDa had the highest DPP-IV 
inhibition rate of 92.5 %, while peptides < 1 kDa displayed an inhibition rate of 75.2%. 
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 9 
Because both groups of ultrafiltered fractions were strong inhibitors, fractions obtained 
from gel filtration were also assayed for DPP-IV inhibitory activity. 
3.2 DPP-IV inhibitory activity of fractions from gel filtration chromatography 225 
Fractions separated using the Sephadex G-25 gel filtration column (Figure 2) were 
assayed for in vitro DPP-IV inhibitory activity at various concentrations each.  
The assays showed that sample 1 (corresponding to an elution volume from 110 to 185 
mL) and samples 3, 4 and 5 (corresponding to elution volumes in the ranges 315 to 625 
mL) did not exert a remarkable inhibitory effect on DPP-IV activity. Moreover, their 230 
concentrations were 0.19 mg/mL for sample 1, 13.54 mg/mL for sample 3, 1.59 mg/mL 
for sample 4 and 7.04 mg/mL for sample 5, each concentration expressed as tyrosine 
equivalents measured at 280 nm. 
Sample 2 corresponding to an elution volume from 190 mL to 310 mL was the only 
sample that showed DPP-IV inhibitory activity. This sample corresponded to molecular 235 
mass lower than 1700 Da (Aristoy & Toldrá, 1995) and its concentration was 5.67 
mg/mL expressed as tyrosine equivalents. The IC50 value was determined and found to 
be 0.69 mg/mL (Figure 3). In addition, we tested the effect of two minerals, sodium and 
calcium, on DPP-IV enzyme activity. In dry-cured ham, current levels of salt added in 
the curing process result in sodium concentrations within the range 1100-1800 mg/100g, 240 
while calcium is usually between 12 and 35 mg/100g of ham (Jiménez-Colmenero, 
Ventanas & Toldrá, 2010). Moreover, former studies showed that the elution of NaCl 
from the gel filtration column appeared in fraction corresponding to sample 2 
(Sentandreu et al., 2003). Then, CaCl2 and NaCl were tested if affected the inhibition 
results obtained for sample 2, but the results indicated that both salts were not DPP-IV 245 
inhibitors. 
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3.3 DPP-IV inhibitory activity of selected peptides 
Four dipeptides identified in dry-cured ham (AA, KA, GP, and PL), three natural meat 
peptides (carnosine, anserine and GSH) and other seven dry-cured ham peptides of 250 
greater length (AAATP, ASGPINFT, DVITGA, SAGPN, AAAAG, ALGGA, and 
LVSGM) were selected and evaluated for their in vitro activity on DPP-IV. Diprotin A 
(Ile-Pro-Ile), which is a well-known peptide with the greatest DPP-IV inhibitory activity, 
was used as a control and showed an IC50 value of 11.08 µM as measured under the 
present study conditions (Figure 4).  255 
The first four dipeptides were mainly generated by the action of porcine muscle 
dipeptidyl peptidases (Sentandreu et al., 2007) and were selected because they contain a 
proline or alanine in the first or second N-terminal residue. The experimental results 
indicated that AA and KA were DPP-IV inhibitors with IC50 of 9.40 ± 0.10 mM and 
6.27 ±0.59 mM, respectively. In relation to GP, contradictory results are reported in the 260 
literature with some studies indicating DPP-IV inhibitory activity (Lacroix et al., 2012) 
and other study indicating the opposite (Hatanaka et al., 2012). In our assay, GP 
presented inhibitory activity and its IC50 value was 9.69 ± 0.49 mM. PL peptide showed 
the lowest inhibitory activity and its IC50 value was found to be greater than 10 mM 
(Table 1). 265 
Marušić, Aristoy & Toldrá, 2013, studied and determined the concentrations of natural 
meat peptides carnosine, anserine and GSH in Biceps femoris muscle during the 
processing of dry-cured ham. At 10 months of ham curing process, concentrations of 
carnosine and anserine were 1269.6 mg/100g of ham dry matter (equivalent to 56 mM) 
and 70.9 mg/100g of ham dry matter (equivalent to 2.95 mM), respectively. GSH was 270 
present until 6.5 months of processing but it disappeared at the end of the process (9 and 
10 months). This tripeptide was not present in our samples but some commercial hams 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 11 
with 5-7 months of curing process still contain GSH (approximately 5-10 µM). So, 
these natural meat peptides were tested as inhibitors and results indicated that anserine 
and GSH did not inhibit the activity of DPP-IV at 10 mM or lower concentrations. 275 
However, carnosine exerted inhibitory activity and its IC50 was 493 ± 4.74 mM (Table 
2). Considering the high concentration of carnosine (56 mM) present in ham after 10 
months of processing, this value would represent an inhibition rate of 13%.  
Regarding to the seven synthesised peptides, all of them were identified previously in 
dry-cured ham. AAATP, ASGPINFT, and DVITGA were described as antihypertensive 280 
peptides, whereas SAGPN did not show ACE inhibitory activity (Escudero et al., 
2013a), and AAAAG, ALGGA, and LVSGM were described as antioxidant peptides 
(Escudero et al., 2013b). More peptides were also identified but only those having a 
length between 2 to 8 amino acids and a hydrophobic nature within the peptide 
sequence, particularly a proline or an alanine in the first or second N-terminal residue, 285 
were selected. As can be seen in Table 1, AAATP was the strongest DPP-IV inhibitor 
with an IC50 value of 6.47 ± 0.20 mM, while AAAAG showed an IC50 value of 8.13 ± 
0.48 mM. Peptides ALGGA and LVSGM were also DPP-IV inhibitors but their IC50 
were greater than 10 mM, and ASGPINFT, DVITGA, and SAGPN did not exert 
inhibitory activity up to 20 mM. 290 
DPP-IV inhibitory peptides AAAAG, ALGGA, and LVSGM were identified in 
fractions, from size-exclusion chromatography, corresponding to our sample 2 
(Escudero et al., 2013b), which is in agreement with the high DPP-IV inhibitory activity 
showed previously in this sample. However, AAATP was identified in fraction 
corresponding to our sample 3 and it was originated from Sus scrofa allantoicase protein 295 
(Escudero et al., 2013a). No inhibitory activity was detected in sample 3, probably due 
to the low amount of AAATP originated from a minor protein (allantoicase) in ham. 
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These findings are of interest because peptides generated in dry-cured ham may act as a 
natural therapeutic approach for the management of type 2 diabetes, although these are 
not as potent as the synthetic drugs. In addition, these biopeptides could be isolated 300 
from dry-cured ham and then be added as ingredients in products marketed as 
‘Functional Foods’ or ‘Natraceuticals’, or they could be used as ingredients of 
pharmaceutical products against type 2 diabetes (Pihlanto & Korhonen, 2003; Hartmann 
& Meisel, 2007; Ryan, Ross, Bolton, Fitzgerald & Stanton, 2011). 
 305 
4. Conclusions 
This study reports, for the first time in Spanish dry-cured ham, the identification of 
peptides that exhibit in vitro DPP-IV inhibitory activity. Nine peptides were shown to 
inhibit DPP-IV enzyme of which KA and AAATP were the most potent inhibitors, with 
IC50 values of 6.27 mM and 6.47 mM, respectively. Therefore, dry-cured ham could 310 
serve as natural precursor of peptides with inhibitory effect on DPP-IV, and these 
biopeptides could be used as a natural complementary treatment in the prevention and 
management of type 2 diabetes. However, further research is needed to identify novel 
peptides responsible for DPP-IV inhibition in dry-cured ham or test a possible 
synergistic effect among various inhibitory peptides identified. Moreover, future in vivo 315 
studies will need to be performed to validate the in vitro DPP-IV inhibitory activity and 
confirm the bioavailability and efficacy of these bioactive peptides.  
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FIGURES CAPTIONS 
Figure 1. DPP-IV inhibitory activity of dry-cured ham extract fractionated by 
ultrafiltration. 
 
Figure 2. Fractionation of dry-cured ham extract in a Sephadex G-25 gel filtration 
column. Fractions were collected and tested for DPP-IV inhibitory activity. Fractions 
corresponding to elution volumes from 110 to 185 mL were pooled and named sample 1 
(S1). The same procedure was followed for fractions corresponding to elution volumes 
from 190 to 310 mL (S2), fractions from 315 to 420 mL (S3), fractions from 425 to 475 
mL (S4) and fractions from 480 to 625 mL (S5). 
 
Figure 3. DPP-IV inhibition rate and IC50 value of sample 2 at various concentrations. 
Bars represent standard deviations from triplicate determinations. 
 
Figure 4. DPP-IV inhibition rate and IC50 value of diprotin A at various concentrations. 
Bars represent standard deviations from triplicate determinations. 
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